IP Library Granted Patent US 10,711,260
Granted Patent B2
US 10,711,260 · App. 16/577,992 · Granted Jul 14, 2020

Histidyl-tRNA synthetase-Fc conjugates

Inventors: Chi-Fang Wu (San Diego, CA); Darin Lee (San Diego, CA); Jeffry D. Watkins (Encinitas, CA); Kristi Piehl (San Diego, CA); Kyle P. Chiang (Cardiff, CA); Marc Thomas (Vista, CA); Minh-Ha Do (San Diego, CA); Ying Buechler (Carlsbad, CA); John D. Mendlein (Encinitas, CA)
Assignee: aTyr Pharma, Inc.
C12N9/93A61P11/00A61P29/00A61P37/00C12N9/96C12Y601/01021C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,711,260
App. No.
16/577,992
Granted
Jul 14, 2020
Kind
B2
Abstract

The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.

Claims (14)

1. An isolated polynucleotide, comprising a nucleotide sequence that encodes a histidyl-tRNA synthetase (HRS) fusion polypeptide having at least one Fc region, where the polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO:337.

2. The isolated polynucleotide of claim 1 , wherein the HRS fusion polypeptide comprises an amino acid sequence at least 97% identical to SEQ ID NO: 337.

3. The isolated polynucleotide of claim 1 , wherein the HRS fusion polypeptide comprises an amino acid sequence at least 98% identical to SEQ ID NO: 337.

4. The isolated polynucleotide of claim 1 , wherein the Fc region and the HRS polypeptide are separated by a peptide linker.

5. The isolated polynucleotide of claim 4 , wherein the peptide linker is about 1-10 amino acids, or 1-5 amino acids in length.

6. The isolated polynucleotide of claim 1 , wherein the polynucleotide is a synthetic DNA or RNA.

7. A vector, comprising the isolated polynucleotide of claim 1 , or a host cell comprising the vector comprising the isolated polynucleotide of claim 1 .

8. A method for manufacturing a histidyl-tRNA synthetase (HRS) fusion polypeptide having at least one Fc region, comprising a) culturing the host cell of claim 7 to express the HRS fusion polypeptide; and b) isolating the HRS fusion polypeptide from the host cell.

9. The method of claim 8 , wherein the host cell is E. coli.

10. The method of claim 9 , wherein the E. coli is the K-12 strain.

11. The method of claim 10 , wherein the K-12 strain is selected from W3110 and UT5600.

12. The method of claim 8 , wherein host cell is a bacterium, yeast, or mammalian cell.

13. An isolated RNA polynucleotide, comprising a nucleotide sequence that encodes a histidyl-tRNA synthetase (HRS) fusion polypeptide having at least one Fc region, where the polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO:337, wherein the RNA polynucleotide is encapsulated in a nanoparticle or liposome.

14. The isolated RNA polynucleotide of claim 13 , comprising a modified cap or tail structure to enhance stability and translation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: BUECHLER, YING; CHIANG, KYLE; DO, MINH-HA; LEE, DARIN; PIEHL, KRISTI; THOMAS, MARC; WATKINS, JEFFRY D.; WU, CHI-FANG; MENDLEIN, JOHN D.
To: ATYR PHARMA, INC.
Reel/Frame 052688/0619 →
Continuity (5)
Continuation 16122231 · Sep 5, 2018
Continuation 15415369 · Jan 25, 2017
Continuation 14214491 · Mar 14, 2014
Provisional Application 61789011 · Mar 15, 2013
Related Publication 20200149028A1 · May 14, 2020
Cited By (3)
US 12,492,392 US 12,497,466 US 12,540,141